Rosiglitazone and the Case for Safety Over Certainty

被引：17

作者：

Juurlink, David N. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON M4N 3M5, Canada

[2] Univ Toronto, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada

[3] Univ Toronto, Dept Pediat, Toronto, ON M4N 3M5, Canada

[4] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M4N 3M5, Canada

[5] Inst Clin Evaluat Sci, Toronto, ON, Canada

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2010年 / 304卷 / 04期

关键词：

ACTIVATED-RECEPTOR-GAMMA; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; PIOGLITAZONE; ASSOCIATION; THERAPY; RISK;

D O I：

10.1001/jama.2010.954

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：469 / 471

页数：3

共 19 条

[1] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[2] Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin [J].

Dormuth, Colin R. ;

Maclure, Malcolm ;

Carney, Greg ;

Schneeweiss, Sebastian ;

Bassett, Ken ;

Wright, James M. .

PLOS ONE, 2009, 4 (06)

[3] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia [J].

Goldberg, RB ;

Kendall, DM ;

Deeg, MA ;

Buse, JB ;

Zagar, AJ ;

Pinaire, JA ;

Tan, MH ;

Khan, MA ;

Perez, AT ;

Jacober, SJ .

DIABETES CARE, 2005, 28 (07) :1547-1554

[4] Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone [J].

Graham, David J. ;

Ouellet-Hellstrom, Rita ;

MaCurdy, Thomas E. ;

Ali, Farzana ;

Sholley, Christopher ;

Worrall, Christopher ;

Kelman, Jeffrey A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (04) :411-418

[5]

*GSK CLIN TRIALS, THIAZ INT VIT D EV

[6] Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial [J].

Home, Philip D. ;

Pocock, Stuart J. ;

Beck-Nielsen, Henning ;

Curtis, Paula S. ;

Gomis, Ramon ;

Hanefeld, Markolf ;

Jones, Nigel P. ;

Komajda, Michel ;

McMurray, John J. V. .

LANCET, 2009, 373 (9681) :2125-2135

[7] Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study [J].

Juurlink, David N. ;

Gomes, Tara ;

Lipscombe, Lorraine L. ;

Austin, Peter C. ;

Hux, Janet E. ;

Mamdani, Muhammad M. .

BMJ-BRITISH MEDICAL JOURNAL, 2009, 339 :562

[8]

JUURLINK DN, 2010, COMMUNICATION 0511

[9] Thiazolidinedione Drugs and Cardiovascular Risks A Science Advisory From the American Heart Association and American College of Cardiology Foundation [J].

Kaul, Sanjay ;

Bolger, Ann F. ;

Herrington, David ;

Giugliano, Robert P. ;

Eckel, Robert H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (17) :1885-1894

[10] Thiazolidinedione-associated congestive heart failure and pulmonary edema [J].

Kermani, A ;

Garg, A .

MAYO CLINIC PROCEEDINGS, 2003, 78 (09) :1088-1091

← 1 2 →